JPWO2022271964A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022271964A5 JPWO2022271964A5 JP2023578891A JP2023578891A JPWO2022271964A5 JP WO2022271964 A5 JPWO2022271964 A5 JP WO2022271964A5 JP 2023578891 A JP2023578891 A JP 2023578891A JP 2023578891 A JP2023578891 A JP 2023578891A JP WO2022271964 A5 JPWO2022271964 A5 JP WO2022271964A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- egfr
- mutated
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214769P | 2021-06-24 | 2021-06-24 | |
| US63/214,769 | 2021-06-24 | ||
| US202163277550P | 2021-11-09 | 2021-11-09 | |
| US63/277,550 | 2021-11-09 | ||
| US202163280521P | 2021-11-17 | 2021-11-17 | |
| US63/280,521 | 2021-11-17 | ||
| US202263321615P | 2022-03-18 | 2022-03-18 | |
| US63/321,615 | 2022-03-18 | ||
| PCT/US2022/034754 WO2022271964A1 (en) | 2021-06-24 | 2022-06-23 | Erk1/2 and shp2 inhibitors combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526155A JP2024526155A (ja) | 2024-07-17 |
| JP2024526155A5 JP2024526155A5 (https=) | 2025-06-24 |
| JPWO2022271964A5 true JPWO2022271964A5 (https=) | 2025-06-24 |
Family
ID=84545944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578891A Withdrawn JP2024526155A (ja) | 2021-06-24 | 2022-06-23 | Ｅｒｋ１／２およびｓｈｐ２阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299388A1 (https=) |
| EP (1) | EP4358965A4 (https=) |
| JP (1) | JP2024526155A (https=) |
| KR (1) | KR20240096444A (https=) |
| AU (1) | AU2022300368A1 (https=) |
| CA (1) | CA3222772A1 (https=) |
| IL (1) | IL309401A (https=) |
| MX (1) | MX2023015298A (https=) |
| TW (1) | TW202317124A (https=) |
| WO (1) | WO2022271964A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016205418A1 (en) * | 2015-06-15 | 2016-12-22 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| CA3074690A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP7542538B2 (ja) * | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| CA3158910A1 (en) * | 2019-10-28 | 2021-05-06 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
-
2022
- 2022-06-23 MX MX2023015298A patent/MX2023015298A/es unknown
- 2022-06-23 EP EP22829313.0A patent/EP4358965A4/en not_active Withdrawn
- 2022-06-23 US US18/572,404 patent/US20240299388A1/en active Pending
- 2022-06-23 KR KR1020247002544A patent/KR20240096444A/ko active Pending
- 2022-06-23 AU AU2022300368A patent/AU2022300368A1/en active Pending
- 2022-06-23 IL IL309401A patent/IL309401A/en unknown
- 2022-06-23 JP JP2023578891A patent/JP2024526155A/ja not_active Withdrawn
- 2022-06-23 CA CA3222772A patent/CA3222772A1/en active Pending
- 2022-06-23 WO PCT/US2022/034754 patent/WO2022271964A1/en not_active Ceased
- 2022-06-23 TW TW111123544A patent/TW202317124A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022271964A5 (https=) | ||
| van der Kleij et al. | Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology: MBA van der Kleij et al. | |
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| Martinelli et al. | Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK | |
| Lee et al. | Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial | |
| Drilon et al. | A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105 | |
| Kohno et al. | RET fusion gene: translation to personalized lung cancer therapy | |
| Lovly et al. | Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies | |
| Giommoni et al. | Results of the observational prospective RealFLOT study | |
| US20240285625A1 (en) | Erk1/2 and kras g12c inhibitors combination therapy | |
| JPWO2023140329A5 (https=) | ||
| CN109715163A (zh) | 包含raf抑制剂和erk抑制剂的治疗组合 | |
| Serra et al. | Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2 V659E mutation | |
| LoConte et al. | A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors | |
| JP7504097B2 (ja) | Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法 | |
| Higuchi et al. | High clinical concordance of drug resistance in patient-derived orthotopic xenograft (PDOX) mouse models: first step to validated precise individualized cancer chemotherapy | |
| JPWO2022170060A5 (https=) | ||
| Janku et al. | Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers | |
| JPWO2022271935A5 (https=) | ||
| Saiki et al. | Characterization of computed tomography imaging of rearranged during transfection-rearranged lung cancer | |
| Riely | New targeted therapies for metastatic non–small cell lung cancer | |
| Filetti et al. | New driver alterations in non-small cell lung cancer. A narrative review | |
| Chowaniecova et al. | An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report | |
| Mori et al. | Clinical outcomes of patients with colorectal cancer who underwent comprehensive genomic profiling: a single-institution non-comparative prospective observational study | |
| JPWO2022125962A5 (https=) |